Molecular investigation of c-MYC oncogene amplification in diabetic patients of Karaj County, Iran Investigating c-MYC Amplification in Diabetics
Archives of Advances in Biosciences,
Vol. 12 No. 3 (2021),
10 July 2021
,
Page 1-10
https://doi.org/10.22037/aab.v12i3.34675
Abstract
Introduction: There is growing evidence revealing that genetic factors could be involved in the etiology of insulin resistance and diabetes. Recent studies now suggest that c-MYC oncogene amplification in beta-cells can cause downregulation of insulin gene expression and leading to diabetes. The present study was carried out to examine gene amplification level of c-MYC gene in healthy individuals compared to those with diabetes.
Materials and Methods : This case control study consisted of 70 subjects (34 diabetic patients and 36 healthy controls). The genomic DNA was extracted from blood samples using standard phenol-chloroform method, and Differential Quantitative PCR (DQ PCR) was accomplished. Subsequently, the mean Band Intensity Ratio (BIR) of c-MYC to γ-IFN was applied to determine the amplified products' molecular band intensity. The Real-time PCR was used to reconfirm the obtained results.
Results: The mean BIR of c-MYC to γ-IFN was 1.29 in diabetics, whereas in healthy individuals, the mean BIR was equal to 1.16.The findings indicate that the mean BIR in diabetics was almost 1.1 times higher than healthy controls; however, it was not statically different (P-value= .168).
Conclusions: Since no significant difference was found in terms of BIR of c-MYC to γ-IFN in case and control groups, it can be concluded that c-MYC may not have a role to trigger the disease in this limited Iranian population. Further studies and larger statistical populations are needed to confirm our findings. This study showed that the DQ PCR technique could be reliable to screen gene amplification in large populations.
- Diabetes; c-MYC oncogene; Gene amplification
How to Cite
References
Association, A.D., Diagnosis and classification of diabetes mellitus. Diabetes care, 2010. 33(Supplement 1): p. S62-S69.
Chatterjee, S., K. Khunti, and M.J. Davies, Type 2 diabetes. The Lancet, 2017. 389(10085): p. 2239-2251.
Eisenbarth, G.S., Type I diabetes mellitus. New England journal of medicine, 1986. 314(21): p. 1360-1368.
Tuomilehto, J., et al., Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine, 2001. 344(18): p. 1343-1350.
Shaw, J.E., R.A. Sicree, and P.Z. Zimmet, Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes research and clinical practice, 2010. 87(1): p. 4-14.
Cho, N., et al., IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes research and clinical practice, 2018. 138: p. 271-281.
Rother, K.I., Diabetes treatment—bridging the divide. The New England journal of medicine, 2007. 356(15): p. 1499.
Parikh, H. and L. Groop, Candidate genes for type 2 diabetes. Reviews in Endocrine and Metabolic Disorders, 2004. 5(2): p. 151-176.
Barroso, I., et al., Candidate gene association study in type 2 diabetes indicates a role for genes involved in β-cell function as well as insulin action. PLoS Biol, 2003. 1(1): p. e20.
Laybutt, D.R., et al., Overexpression of c-Myc in β-cells of transgenic mice causes proliferation and apoptosis, downregulation of insulin gene expression, and diabetes. Diabetes, 2002. 51(6): p. 1793-1804.
Pelengaris, S. and M. Khan, The many faces of c-MYC. Archives of biochemistry and biophysics, 2003. 416(2): p. 129-136.
Ye, J., et al., Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC bioinformatics, 2012. 13(1): p. 1-11.
Adams, J., et al., The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature, 1985. 318(6046): p. 533-538.
Kaneto, H., et al., Induction of c-Myc expression suppresses insulin gene transcription by inhibiting NeuroD/BETA2-mediated transcriptional activation. Journal of Biological Chemistry, 2002. 277(15): p. 12998-13006.
Jonas, J.-C., et al., High glucose stimulates early response gene c-Myc expression in rat pancreatic β cells. Journal of Biological Chemistry, 2001. 276(38): p. 35375-35381.
Collier, J.J., et al., c-Myc is required for the glucose-mediated induction of metabolic enzyme genes. Journal of Biological Chemistry, 2003. 278(8): p. 6588-6595.
Nicolson, T.J., et al., Insulin storage and glucose homeostasis in mice null for the granule zinc transporter ZnT8 and studies of the type 2 diabetes–associated variants. Diabetes, 2009. 58(9): p. 2070-2083.
Cheung, L., et al., c-Myc directly induces both impaired insulin secretion and loss of β-cell mass, independently of hyperglycemia in vivo. Islets, 2010. 2(1): p. 37-45.
Vairaktaris, E., et al., Diabetes alters expression of p53 and c-myc in different stages of oral oncogenesis. Anticancer research, 2007. 27(3B): p. 1465-1473.
- Abstract Viewed: 328 times
- PDF Downloaded: 296 times